![](https://monteverdelaw.com/wp-content/uploads/case-logo/turning-point-therapeutics-inc.jpg)
Turning Point Therapeutics, Inc. (TPTX), relating to its proposed acquisition by Bristol-Meyers Squibb Co. Under the terms of the agreement, TPTX shareholders will receive $76.00 in cash per share they own.
Turning Point Therapeutics, Inc. (TPTX), relating to its proposed acquisition by Bristol-Meyers Squibb Co. Under the terms of the agreement, TPTX shareholders will receive $76.00 in cash per share they own.